A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …

Glioblastoma (GBM), an aggressive high-grade glial tumor, is resistant to therapy and has a
poor prognosis due to its universal recurrence rate. GBM cells interact with the non-cellular …

The limited efficacy of immunotherapies against glioblastoma underscores the urgency of
better understanding immunity in the central nervous system. We found that treatment with …

Glioblastoma is the most common malignant primary central nervous system tumor and one
of the most debilitating cancers. The prognosis of patients with glioblastoma remains poor …

The most widely used fluorophore in glioma-resection surgery, 5-aminolevulinic acid (5-
ALA), is thought to cause the selective accumulation of fluorescent protoporphyrin IX (PpIX) …

Background Radiotherapy is the primary therapeutic option for glioblastoma. Some studies
proved that radiotherapy increased the release of exosomes from cells. The mechanism by …

Increase of deposits of amyloid β peptides in the extracellular matrix is landmark during
Alzheimer's Disease (AD) due to the imbalance in the production vs. clearance. This …

Glioblastoma, a grade IV astrocytoma, is regarded as the most aggressive primary brain
tumour with an overall median survival of 16.0 months following the standard treatment …

Type I interferons have long been appreciated as a cytokine family that regulates antiviral
immunity. Recently, their role in eliciting antitumor immune responses has gained increasing …

Glioblastoma (GBM) is an aggressive and highly malignant primary brain tumor
characterized by rapid growth and a poor prognosis for patients. Despite advancements in …